All figures below are taken from Summit’s Form 10-K for 2024 (SEC 10-K 2024) and from its 2024 and Q3 2025 financial results press releases (FY2024 PR – 24 Feb 2025, Q3 2025 PR – 20 Oct 2025).

2024 net loss and cash-flow data are from the Form 10-K (see “Consolidated Statements of Operations” and “Statements of Cash Flows”). Net loss and cash/balance-sheet figures for Q3 2025 come directly from the unaudited GAAP tables in the 20 October 2025 press release.

Summit Therapeutics Inc. (NASDAQ: SMMT) has effectively transformed itself into a single-asset, late-stage oncology company centered on ivonescimab (SMT112), a PD-1 × VEGF bispecific antibody licensed from Akeso in January 2023 (FY2024 PR). Ivonescimab is already approved in China (Akeso) and is now in a broad, global Phase III program led by Summit in NSCLC and colorectal cancer.

The Phase III HARMONi trial – the first global Phase III study of ivonescimab – met its primary endpoint of progression-free survival (PFS), reducing the risk of disease progression or death by 48% compared to chemotherapy alone in EGFR-mutated NSCLC after 3rd-generation EGFR TKI therapy (topline announced May 2025 and reiterated in the Q3 2025 PR, plus WCLC 2025 communication) (WCLC 2025 PR; Q3 2025 PR). Overall survival (OS), the co-primary endpoint, showed a positive trend but did not achieve statistical significance in the first topline disclosure – a nuance that triggered sell-offs and later class-action investigations by plaintiff firms Portnoy and Pomerantz.

At the same time, Summit is rapidly expanding the ivonescimab program: global Phase III trials HARMONi-3 (1L metastatic NSCLC, ivonescimab+chemo vs pembrolizumab+chemo), HARMONi-7 (1L PD-L1 high NSCLC, ivonescimab vs pembrolizumab monotherapy), and the new HARMONi-GI3 (1L metastatic colorectal cancer, ivonescimab+chemo vs bevacizumab+chemo) have been launched or expanded in 2024–2025 (HARMONi-GI3 PR – 17 Oct 2025; FY2023 PR – 20 Feb 2024).

On the financial side, Summit’s 2024 Form 10-K shows a GAAP net loss of ~221 M USD (vs 615 M USD in 2023, when it booked a large in-process R&D charge for the Akeso license) and net cash used in operations of ~142 M USD (10-K 2024). The Q3 2025 PR reports cash + short-term investments of 238.6 M USD at 30 September 2025, down from 412.3 M USD at year-end 2024, and a GAAP net loss of 231.8 M USD for Q3 2025 alone, driven largely by very high stock-based compensation linked to performance-based option modifications (Q3 2025 PR).

With the JPM 2026 presentation set for January 12, 2026 at 9:45 a.m. PT in San Francisco (JPM PR – 6 Jan 2026; event page), Summit’s message is clear: ivonescimab is a global, multi-tumor Phase III program aimed at reshaping NSCLC and CRC treatment – but the story is high beta, highly concentrated on a single asset and now under both regulatory and legal market scrutiny.

Single-asset, late-stage oncology story with a very large Phase III footprint, heavy cash burn, highly volatile share price and ongoing class-action investigations. This section is informational only, not a buy/sell view.

Historically, Summit Therapeutics operated as an anti-infectives company, but the 2022–2023 strategic pivot – anchored by the licensing agreement with Akeso for ivonescimab – turned it into an oncology company. The FY2024 10-K notes a 2024 net loss of 221.3 M USD, substantially lower than 2023’s 614.9 M USD, largely because 2023 included a 520.9 M USD acquired in-process R&D charge tied to the Akeso license. :contentReference[oaicite:0]{index=0}

Ivonescimab (SMT112) is described in Summit’s 2023 and 2024 result PRs as a “potentially first-in-class, PD-1 and VEGF-targeting, bispecific antibody” combining immune checkpoint inhibition (PD-1 blockade) and anti-angiogenic effects (VEGF inhibition) in a single molecule (FY2023 PR; FY2024 PR).

Summit’s monetization strategy, as summarized in the FY2024 PR, rests on three main pillars:

• a strong Phase III evidence base in NSCLC (HARMONi and HARMONi-6, plus global HARMONi-3 and HARMONi-7);
• expansion into 1L colorectal cancer with HARMONi-GI3;
• strategic partnerships, such as the clinical collaboration with Pfizer to evaluate ivonescimab in combination with vedotin-based ADCs (Summit–Pfizer PR – 24 Feb 2025).

The ivonescimab clinical pipeline is now described in detail across Summit’s and Akeso’s official press releases:

• HARMONi (global Phase III, 2L+ EGFRm NSCLC after 3rd-gen EGFR TKI)
  – Ivonescimab + chemotherapy vs placebo + chemotherapy; enrollment was completed in 2H 2024 and topline data were announced in May 2025. The primary PFS endpoint was met, with an HR of about 0.52–0.60 (≈48% reduction in risk of progression or death) and an OS result showing a favorable trend but not achieving statistical significance at the first analysis (FY2024 PR operational update; Q3 2025 PR; WCLC 2025 PR “Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium”). :contentReference[oaicite:1]{index=1}
• HARMONi-3 (global Phase III, 1L metastatic NSCLC)
  – Ivonescimab + chemotherapy vs pembrolizumab + chemotherapy; initially designed for non-squamous disease and subsequently expanded to include both squamous and non-squamous cohorts (FY2024 PR operational update; Q3 2025 PR line 104). Analyses for HARMONi-3 will be split by histology; Summit currently expects to complete enrollment in the squamous cohort in 1H 2026 with a PFS readout in 2H 2026, and to complete enrollment in the non-squamous cohort in 2H 2026 with a PFS readout around 1H 2027. :contentReference[oaicite:2]{index=2}
• HARMONi-7 (global Phase III, 1L PD-L1 high NSCLC)
  – Ivonescimab monotherapy vs pembrolizumab monotherapy; trial sites were activated in 2024/early 2025 (FY2024 PR lines 104–106; Q3 2025 PR line 106).
• HARMONi-GI3 (global Phase III, 1L metastatic CRC)
  – Ivonescimab + chemotherapy vs bevacizumab + chemotherapy; this is the first global Phase III trial of ivonescimab beyond NSCLC. The October 17, 2025 press release describes HARMONi-GI3 as a ~600-patient study with PFS as the primary endpoint; trial sites in the United States are planned to begin activation before year-end 2025 (HARMONi-GI3 PR). :contentReference[oaicite:3]{index=3}
• Akeso single-region Phase III data (China) – HARMONi-A, HARMONi-2, HARMONi-6
  – Summit’s WCLC 2025 PR and Q3 2025 PR (lines 101–103) highlight Akeso’s data:
  • HARMONi-A: ivonescimab + chemotherapy vs placebo + chemotherapy in EGFRm NSCLC after EGFR TKI; updated OS PR from 7 Nov 2025 reports a statistically significant OS benefit with HR 0.74 in this 2L+ setting (HARMONi-A OS PR – 7 Nov 2025); :contentReference[oaicite:4]{index=4}
  • HARMONi-6: ivonescimab + chemotherapy vs tislelizumab + chemotherapy in 1L squamous NSCLC; PFS HR 0.60 (≈40% risk reduction), with full results presented at ESMO 2025 and published in The Lancet (HARMONi-6 PR – 19 Oct 2025). :contentReference[oaicite:5]{index=5}
• BLA timeline
  – The Q3 2025 PR (headline & bullet points) states that Summit “plans to submit a BLA in Q4 2025 for ivonescimab based on HARMONi global Phase III study results” and that further Phase III trials will be detailed in Q1 2026 (Q3 2025 PR). :contentReference[oaicite:6]{index=6}

The 2024 10-K and the FY2024 PR show a meaningful shift in Summit’s P&L structure vs 2023 (10-K; FY2024 PR):

• Net loss – 2024 GAAP net loss ~221.3 M USD (vs ~614.9 M USD in 2023). The 2023 figure was inflated by a ~520.9 M USD acquired in-process R&D charge related to the Akeso license; 2024 shows a more “normalized” burn but still substantial.
• Cash & investments – cash, cash equivalents and short-term investments 412.3 M USD at 31 Dec 2024 (Q3 2025 PR balance sheet: 412.3 vs 238.6 M USD at 30 Sep 2025). :contentReference[oaicite:7]{index=7}
• Q3 2025 results – for the quarter ended 30 Sep 2025, GAAP net loss was 231.8 M USD; for the nine months ended 30 Sep 2025, GAAP net loss was 860.4 M USD (Q3 PR, GAAP statement of operations). :contentReference[oaicite:8]{index=8}
• Operating cash flow – net cash used in operating activities in 2024 was 142.1 M USD (10-K cash-flow table). For 9M 2025, net cash used in operations was 221.0 M USD (Q3 PR cash-flow table). :contentReference[oaicite:9]{index=9}
• Stock-based compensation – Q3 2025 PR explains that GAAP R&D and G&A are heavily inflated by performance-based stock option modifications (R&D stock-based comp 173.2 M USD YTD; G&A stock-based comp 447.4 M USD YTD, for a total 620.6 M USD non-cash; GAAP vs non-GAAP reconciliation). :contentReference[oaicite:10]{index=10}

In other words: the 2023–2024 pivot into oncology and the 2025 expansion of the ivonescimab program have left Summit with a normalized annual cash-burn in the low-hundreds of millions and a 9M 2025 GAAP net loss approaching 860 M USD, partly driven by non-cash stock-based compensation.

Summit’s recapitalization and dilution history is detailed in its 10-K and in the rights offering and Akeso-deal disclosures (2022–2023). Key recent points:

• The FY2024 10-K shows a year-end 2024 cash+short-term investment position of ~412.3 M USD (cash 16.3 M, money-market funds 88.6 M, US T-bills 307.5 M). :contentReference[oaicite:11]{index=11}
• Q3 2025 basic/diluted common shares used for GAAP EPS are 743.4 M for the quarter and 741.4 M for 9M 2025 (Q3 PR reconciliation tables). :contentReference[oaicite:12]{index=12}
• The 10-K lists 68.9 M stock options and 4.63 M warrants as potentially dilutive securities outstanding at 31 Dec 2024, but all excluded from diluted EPS due to net loss (anti-dilutive). :contentReference[oaicite:13]{index=13}
• Law-firm releases from Portnoy and Pomerantz in September 2025 indicate that shareholder lawsuits are being explored around Summit’s May and September 2025 disclosures on HARMONi OS and region-by-region efficacy differences (Portnoy Law alert, 9 Sep 2025; Pomerantz alert, 10 Sep 2025).

By themselves, these elements do not change the regulatory path of ivonescimab, but they add noise and may temper the willingness of some institutional investors to increase their position in SMMT until the picture is clearer.

Beyond the core partnership with Akeso, Summit has two key strategic fronts:

• Collaboration with Pfizer on vedotin-based ADCs
  – On February 24, 2025 Summit announced a clinical trial collaboration with Pfizer to evaluate ivonescimab in combination with several vedotin-based ADCs in selected solid tumors (Summit–Pfizer PR; BiopharmaDive coverage). Trials are expected to start in mid-2025; each company retains rights to its own drugs.
• Discussions around a potential mega-licensing deal with AstraZeneca
  – A Reuters note (July 3, 2025) based on Bloomberg reporting indicated that Summit and AstraZeneca were discussing a licensing deal for ivonescimab of up to 15 Bn USD, with a large upfront and milestones (Reuters on potential AstraZeneca deal). The companies have not confirmed terms, and Reuters clearly states that the deal may never materialize.

In this context, the JPM 2026 appearance is a natural moment to update the market on: (1) the status of the BLA, (2) Phase III plans for 2026–2027, and (3) any official developments on major partnerships.

For live figures (share price, market cap, volumes), it is better to refer directly to real-time data providers:

• Yahoo Finance – SMMT
• Nasdaq – SMMT

On the media side, a February 24, 2025 article on Investopedia summarizes how the market perceived the company after Q4 2024 results and the Pfizer collaboration: non-GAAP quarterly net loss of 50.2 M USD (0.07 USD per share), roughly double the prior-year quarterly non-GAAP loss, but a share price that had still quadrupled over 12 months on expectations around ivonescimab and big pharma deals (Investopedia – 24 Feb 2025).

The two waves of class-action announcements (Portnoy, Pomerantz) following the 2025 HARMONi updates suggest that part of the market sees a gap between Summit’s narrative and its interpretation of PFS/OS data, but the situation is still evolving.

• Single-asset risk – Summit today is effectively a one-product company built around ivonescimab; any clinical or regulatory issue on this asset directly impacts the whole equity story.
• OS and regional heterogeneity – HARMONi met the PFS endpoint but did not demonstrate a statistically significant OS benefit at the first topline. PRs and independent writeups (Oncodaily, EGFRcancer.org and others) highlight region-specific differences in the OS data (EGFRcancer.org summary). How FDA and EMA will weigh a strong PFS signal with more complex OS results is not straightforward.
• Cash burn and dilution – net loss of 221 M USD in 2024 and 860 M USD in the first nine months of 2025; non-GAAP R&D and G&A remain very high, and cash fell from 412 M to 239 M USD within three quarters. Even after the heavy non-cash component related to awards, the need for additional capital or a strong partner remains structural.
• Class actions & disclosure risk – the Portnoy and Pomerantz investigations point to legal risk around how Summit communicated HARMONi and region-by-region data; it is too early to assess outcomes, but they represent an overhang.
• Deal risk – rumours about an AstraZeneca licensing agreement and, more broadly, the search for a “big partner” imply that part of the current valuation already embeds the expectation of a sizeable deal; if such an agreement fails to materialize, some of that premium could unwind.

Based solely on SEC filings, official PRs and mainstream coverage, Summit Therapeutics, on the eve of JPM 2026, looks like:

• a late-stage, single-asset story built around ivonescimab (PD-1×VEGF) with multiple global Phase III trials in NSCLC and CRC;
• a company with large losses and accelerating cash burn, but still a cash position which – according to Q3 2025 data – offers several quarters of runway;
• a potential partner target for big pharma, with Pfizer already collaborating on ADCs and press speculation about a mega-licensing deal with AstraZeneca, but with HARMONi OS and legal issues that need to be monitored.

This report expresses no operational recommendation; it is simply a numerical and documentary base from which subsequent analyses can start (including your own Deep Dive of December 28, 2025).

Nature of the content. This article is for information and educational purposes only. It is based on publicly available sources such as SEC filings (10-K, 10-Q), the company’s investor-relations website and press releases, clinical-trial registries and reputable news outlets (Reuters, FT, Investopedia, BiopharmaDive). Data may contain errors or become outdated; readers should always verify numbers and events directly from primary documents.

No investment advice. This report does not constitute, and must not be interpreted as, investment advice, individualized financial recommendation, solicitation or invitation to buy or sell financial instruments. No explicit or implicit view is expressed here about the convenience, fairness or appropriateness of any investment in SMMT or in any other security mentioned.

Risk warning. Late-stage, pre-commercial biotech equities, especially single-asset stories like Summit Therapeutics, are highly speculative and volatile. Investors can lose all or a substantial part of the capital invested. Anyone considering exposure to such instruments should evaluate their own objectives, risk tolerance and time horizon and, where appropriate, consult a qualified and regulated financial advisor.